comparemela.com

Latest Breaking News On - Nasdaq sava - Page 7 : comparemela.com

These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022

No Evidence of Data Manipulation in Science Publication on

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s.

Brokerages Anticipate Cassava Sciences, Inc (NASDAQ:SAVA) Will Announce Earnings of -$0 42 Per Share

Equities analysts forecast that Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) will announce earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Cassava Sciences’ earnings, with estimates ranging from ($0.50) to ($0.26). Cassava Sciences reported earnings of ($0.13) per share in the same quarter […]

Cassava Sciences, Inc (NASDAQ:SAVA) Receives Average Recommendation of Hold from Brokerages

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) has received an average recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 […]

Analysts Set Cassava Sciences, Inc (NASDAQ:SAVA) Price Target at $127 75

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) has earned an average rating of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.